Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Novozymes A/S (NVZMF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Novozymes A/S $24.05, price $65.11, upside -63.1%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
NA
Broad data
Oct 3, 2026
Broad data
Oct 3, 2026
Novozymes A/S
NVZMF · USStretched ValuationStrong overvaluation with only moderate quality.
!Fair value $24.05 · Strongly overvalued (−63.1%)
✓Quality 62/100
!Weak Growth (revenue 5y −21.6 %/yr)
✓Solidly profitable · 14.2% net margin (TTM)
✓Low debt · generates free cash flow
✓1.3% dividend yield · Well covered
!Moderate moat 57/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range $37.37 – $75.94 · fair‑value band $16.60 – $33.85 · the $65.11 price screens above the $24.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Company profile
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America.
Show more
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
Stock analysis
Novozymes A/S (NVZMF) currently trades at $65.11, while our model-based Fair Value estimate is $24.05, 63.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $27.08 per share, and 0 of the 24 models we run sit above the $65.11 price.
Bear case: the Dividend Discount group reads lowest at $11.05, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: $16.60 (bear) to $33.85 (bull), the price of $65.11 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Novozymes A/S reported revenue of €4.2B in FY2025 versus €15.0B in FY2021, a compound −27.4%/yr. Reported net income was €584M in FY2025, compounding −34.4%/yr from FY2021.
Key figures
Market cap $30.4B · P/E ratio 39.1 · P/S ratio 5.49 · EPS (TTM) $1.49 · Dividend yield 1.3% · Net margin 14.0% · Return on equity 5.4% · Return on assets (EBIT) 11.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 26% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −63%, NVZMF screens richer than that median.
Fair Value models
Bear $16.60
Fair Value $24.05
Bull $33.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.4688 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$16.68
$24.58
$39.20
79
Growth DCF
$17.62
$25.28
$38.39
78
Residual Income
$23.30
$24.10
$25.65
76
All 24 models by family
DCF Models
FCF DCF
$16.68
$24.58
$39.20
79
Owner Earnings
$15.01
$22.25
$35.65
75
5Y Revenue Exit
$11.03
$16.48
$24.37
72
5Y EBITDA Exit
$20.01
$32.02
$47.93
74
5Y P/E Exit
$15.00
$23.35
$33.34
70
10Y Revenue Exit
$12.78
$17.04
$21.50
68
10Y EBITDA Exit
$18.55
$26.66
$35.33
69
10Y P/E Exit
$15.51
$21.29
$26.76
65
Earnings-Based
Graham-Dodd
$10.83
$13.24
$14.89
67
EPV
$15.36
$18.49
$21.23
74
Dividend Discount
Gordon GGM
$10.09
$11.05
$12.50
69
DDM Multi-Stage
$10.09
$12.66
$16.26
67
Multiples
P/E Multiple
$20.31
$27.08
$33.85
63
P/S Multiple
$12.77
$17.02
$21.28
58
P/B Multiple
$20.31
$27.08
$33.85
55
EV/EBIT
$21.87
$30.30
$38.73
66
EV/EBITDA
$26.41
$36.35
$46.29
67
EV/Revenue
$8.49
$13.59
$18.70
53
Asset-Based
NCAV (Graham)
$14.81
$19.85
$29.63
54
Growth DCF
Growth DCF
$17.62
$25.28
$38.39
78
Rev-Margin DCF
$11.03
$16.95
$24.33
72
Economic Profit
Residual Income
$23.30
$24.10
$25.65
76
ROIC Compounder
$15.36
$18.49
$21.23
72
Growth Earnings
Growth-Adj P/E
$14.47
$20.67
$26.87
67
Notify me when NVZMF reaches fair value
Put NVZMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
62/100
Of which business quality 61 · Market factors (momentum, volatility) 53
Profitability
32
Margins and returns on capital today
Quality Growth
66
Are margins and returns improving?
Cashflow
80
Earnings quality: real cash, not paper profit
Fin. Strength
80
Balance sheet, leverage, solvency risk
Investment
83
Disciplined investing over empire-building
Low Volatility
59
Calm price path (market factor)
Momentum
52
Price trend over the last 3–12 months (market factor)
52W Momentum
50
Distance to the 52-week high (market factor)
Net Issuance
29
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.6%
Start year 2020 (pandemic). Over 10 years: −11.4% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−34.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−35.3%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−35.3% vs −18.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 21%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 13.8%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.7% a year for the price.
NVZMF screens overvalued: fair value 63% below the price. Compare with Linde plc →
Earlier news
News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
- Novozymes (CPSE:NSIS B) Could Be 13% Undervalued After €600 Million Patalganga Expansion
- Novonesis (Novozymes) B's Dividend Analysis
- Novonesis (Novozymes) B (NVZMF) (H1 2026) Earnings Call Highlights: Raises Guidance on 8% ...
- Novozymes Q2 revenue up 9.8% Y/Y; raises FY26 organic sales growth outlook, inaugural €1B share buyback plan
Compare Novozymes A/S with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $474.65 | $441.72 | −7% |
| The Sherwin-Williams Company SHW | $330.44 | $151.68 | −54% |
| Ecolab Inc ECL | $274.58 | $96.56 | −65% |
| Air Products and Chemicals, Inc APD | $279.19 | $121.30 | −57% |
| Nan Ya Plastics Corporation 1303 | 238.00 TWD | 234.23 TWD | −2% |
| Givaudan SA GIVN | CHF 3,360 | CHF 1,527 | −55% |
| Wanhua Chemical Group 600309 | ¥69.45 | ¥68.03 | −2% |
| DSM-Firmenich AG DSFIR | CHF 92.30 | CHF 29.70 | −68% |
| Asian Paints Limited ASIANPAINT | ₹2,444 | ₹1,479 | −39% |
| PPG Industries, Inc PPG | $104.67 | $76.98 | −26% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Novozymes A/S (NVZMF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $24.05 versus a price of $65.11, about −63% upside (overvalued).
What is the fair value of NVZMF?
Our model-based fair value for Novozymes A/S is $24.05 (as of Oct 3, 2026), built from audited fundamentals. The current price: $65.11.
What is the quality score of NVZMF?
Novozymes A/S has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novozymes A/S (NVZMF)?
Our model-based price target is the fair value of $24.05 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario $16.60, optimistic scenario $33.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Novozymes A/S stock forecast for 2026?
Our models put fair value at $24.05, about −63% upside versus a price of $65.11 (overvalued). Cautious scenario $16.60, optimistic scenario $33.85. The calculation is refreshed regularly with new filings.
What is the revenue of Novozymes A/S (NVZMF)?
Novozymes A/S reported trailing-twelve-month revenue of about $4.2B (latest available figure, as of Oct 3, 2026).
Does Novozymes A/S pay a dividend?
Novozymes A/S currently shows a dividend yield of about 1.34% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Novozymes A/S (NVZMF)?
For today's price to be fair in a discounted-cash-flow model, Novozymes A/S would have to grow free cash flow by +19.5 % per year for five years (discount rate 8.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -21.6 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of NVZMF use?
Our models discount Novozymes A/S at 8.4 %: a base by market capitalisation (large), damped by beta 0.62, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Novozymes A/S that is +19.5 % per year a year over ten years, using the same discount rate (8.4 %) and the same formula as our fair value.
How much growth has Novozymes A/S (NVZMF) delivered so far?
Over the past 5 years revenue at Novozymes A/S grew -21.6 % a year. The price currently implies +19.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Novozymes A/S (NVZMF) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Novozymes A/S (+19.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Novozymes A/S (NVZMF)?
The free-cash-flow yield on the price is 2.47 %: that much free cash flow Novozymes A/S produces per unit of market value. When it exceeds the discount rate of our models (8.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Novozymes A/S (NVZMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novozymes A/S it is $24.05 per share (as of Oct 3, 2026), against a price of $65.11. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Novozymes A/S stock overvalued or undervalued in 2026?
As of Oct 3, 2026, NVZMF trades above its calculated fair value: price $65.11, fair value $24.05, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NVZMF?
No. The price is what the market pays today ($65.11); the fair value is what the company's own numbers justify ($24.05). For Novozymes A/S the two are $41.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Novozymes A/S worth?
The market values Novozymes A/S at about $30.4B (market capitalisation, as of Oct 3, 2026). Per share that is $65.11; our models calculate a fair value of $24.05 per share.
What do the bullish and bearish scenarios say about NVZMF?
Our models span a range for Novozymes A/S: cautious scenario $16.60, base $24.05, optimistic $33.85 per share (as of Oct 3, 2026, price $65.11). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is NVZMF from its 52-week high?
Novozymes A/S trades at $65.11, about 8% below its 52-week high of $71.12 and 26% above the low of $51.47 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $24.05 is for.
Which stocks are comparable to Novozymes A/S?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novozymes A/S stock attractive at the current price?
The data as of Oct 3, 2026: price $65.11, calculated fair value $24.05 (−63%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NVZMF calculated?
We run Novozymes A/S through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $24.05, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Novozymes A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novozymes A/S (NVZMF)?
The closing price on Oct 2, 2026 was $65.11. Our model-based fair value is $24.05, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novozymes A/S right now?
The price sits above even our optimistic bull case ($33.85). The favourable scenario is already priced in. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($16.60 to $33.85) leaves room in how you read the outcome.
Where does the earnings growth of Novozymes A/S (NVZMF) come from?
Earnings per share at Novozymes A/S grew −10.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share −7.6 %, EBIT margin −3.2 %, tax rate −0.1 %, residual (interest, one-offs) −0.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Novozymes A/S
How large is the market capitalisation of Novozymes A/S (NVZMF)?
The market capitalisation of Novozymes A/S is $30.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Novozymes A/S (NVZMF)?
The price-to-earnings ratio of Novozymes A/S is 39.1 (as of Jun 22, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Novozymes A/S (NVZMF)?
The price-to-sales ratio of Novozymes A/S is 5.49 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Novozymes A/S (NVZMF)?
Earnings per share at Novozymes A/S are $1.49 (price ÷ EPS = P/E 39.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Novozymes A/S (NVZMF)?
The dividend yield of Novozymes A/S is 1.3% (payout 58.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novozymes A/S (NVZMF)?
The net margin of Novozymes A/S is 14.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novozymes A/S (NVZMF)?
The return on equity (ROE) of Novozymes A/S is 5.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novozymes A/S (NVZMF)?
On an EBIT basis the return on assets of Novozymes A/S is 11.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novozymes A/S (NVZMF)?
The operating margin of Novozymes A/S is 24.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novozymes A/S (NVZMF)?
Revenue at Novozymes A/S is growing +3.9% versus a year earlier (3y avg −38.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Novozymes A/S (NVZMF)?
Earnings per share at Novozymes A/S are growing +7.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Novozymes A/S (NVZMF) carry?
The net debt of Novozymes A/S is $2.7B (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.